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Background: The cardiovascular (CV) safety of linagliptin was evaluated in subjects with type 2 diabetes (T2DM).
Methods: Pre-specified patient-level pooled analysis of all available double-blind, randomized, controlled
trials, ≥12 weeks’ duration (19 trials, 9459 subjects) of linagliptin versus placebo/active treatment. Primary end
point: composite of prospectively adjudicated CV death, non-fatal myocardial infarction, non-fatal stroke, and
hospitalization for unstable angina (4P-MACE). Hospitalization for congestive heart failure (CHF) was also evaluated;
adjudication of CHF was introduced during the phase 3 program (8 trials; 3314 subjects). 4P-MACE was assessed in
placebo-controlled trials (subgroup of 18 trials; 7746 subjects). Investigator-reported events suggestive of CHF from
24 placebo-controlled trials (including trials <12 weeks’ duration, 8778 subjects) were also analyzed.
Results: 5847 patients received linagliptin (5 mg: 5687, 10 mg: 160) and 3612 comparator (glimepiride: 775, voglibose:
162, placebo: 2675); cumulative exposure, 4421.3 and 3254.7 patient-years, respectively. 4P-MACE incidence rates:
13.4 per 1000 patient-years, linagliptin (60 events), 18.9, total comparators (62 events); overall hazard ratio (HR), 0.78
(95% confidence interval [CI], 0.55–1.12). HR for adjudicated hospitalization for CHF (n = 21): 1.04 (0.43–2.47). For
placebo-controlled trials, 4P-MACE incidence rates: 14.9 per 1000 patient-years, linagliptin (43 events), 16.4, total
comparators (29 events); overall HR, 1.09 (95% CI, 0.68–1.75). Occurrence of investigator-reported events suggestive
of CHF was low for linagliptin- (26 events, 0.5%; serious: 16 events, 0.3%) and placebo-treated (8 events, 0.2%; serious:
6 events, 0.2%) patients.
Conclusions: Linagliptin is not associated with increased CV risk versus pooled active comparators or placebo in
patients with T2DM.
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Cardiovascular (CV) disease (CVD) is the major cause
of premature death in patients with type 2 diabetes mel-
litus (T2DM), with approximately half of all deaths at-
tributable to CV complications [1,2]. An important
consideration in the treatment of T2DM is the manage-
ment of CV risk factors, including hyperglycemia, being
closely and independently associated with increased CV* Correspondence: odd_erik.johansen@boehringer-ingelheim.com
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creativecommons.org/publicdomain/zero/1.0/morbidity and premature mortality [3]. Evaluation of
the CV effects of drugs used to lower blood glucose in
T2DM is important, as illustrated by the controversy
surrounding certain glucose-lowering drugs, such as
rosiglitazone [4]. For other drugs, in particular the sul-
fonylureas (SUs) [5], the CV safety is contentious, with
some reports suggesting an increased CV risk with cer-
tain SUs [6-8], while others report no increased risk
[9,10]. Given the relationship between CV safety and
T2DM and the uncertainty surrounding the CV risk of
some therapies, the US Food and Drug Administrationss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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being developed as therapies for T2DM [11]. Conse-
quently, several trials are currently under way to evaluate
the long-term CV outcomes of recently developed drugs.
The first 2 placebo-controlled trials (SAVOR-TIMI 53 and
EXAMINE) involving the dipeptidyl peptidase (DPP)-4 in-
hibitors saxagliptin and alogliptin, respectively, both re-
ported a neutral effect on a composite of CV death
(including fatal stroke and fatal myocardial infarction
[MI]), non-fatal MI, and non-fatal stroke (3P-MACE)
[12,13]. Neither SAVOR-TIMI 53 nor EXAMINE showed
an increase in death from any cause versus placebo
(hazard ratio [HR], 1.11, 95% confidence interval [CI],
0.96–1.27; P = .15, and HR, 1.03, 95% CI, 0.87–1.22;
P = .72, respectively) or death from CV causes (HR, 0.79,
95% CI, 0.60–1.04; P = .10, and HR, 0.88, 95% CI, 0.71–
1.09; P = .23, respectively). Of note, a statistically signifi-
cant increased risk for hospitalization for congestive heart
failure (CHF) associated with saxagliptin therapy was re-
ported, and an analysis of data for alogliptin showed a
non-significant HR above 1.0 [14]. A recent analysis of the
end point of hospitalization for heart failure in SAVOR-
TIMI 53 showed that saxagliptin therapy was associated
with an increased risk of this event: more patients treated
with saxagliptin (289, 3.5%) were hospitalized for heart
failure compared with those allocated to placebo (228,
2.8%; HR, 1.27; 95% CI, 1.07–1.51; P = .007) [15]. This in-
crease was greatest among patients with elevated levels of
natriuretic peptides at baseline, previous heart failure, or
chronic kidney disease. At present it remains unclear
whether any potential increase in CHF is a causal effect.
Linagliptin is a selective and potent DPP-4 inhibitor with
a xanthine-based molecular structure, and is indicated for
the treatment of T2DM. The pharmacokinetic properties of
linagliptin permit DPP-4 inhibition over 24 hours following
once-daily dosing, and the drug is primarily excreted
via the bile and gut [16,17]. In 2010, a pre-specified
meta-analysis of CV events from 8 phase 3 studies was
performed for linagliptin versus overall comparator-treated
patients with T2DM [18]. All suspected CV events and
fatalities were prospectively adjudicated by a blinded, inde-
pendent clinical event committee (CEC). The primary end
point was a composite of CV death, stroke, MI, and
hospitalization for unstable angina (4P-MACE). Although
the analysis was limited in terms of patient numbers (n =
5239) as well as total number of primary events (n = 34), this
initial pooled CV analysis did not indicate any increased risk
of CV events with linagliptin.
Following completion of several other phase 3 studies of
linagliptin, contributing to a larger database than was previ-
ously available, the pooled analysis presented here provides
a more comprehensive and up-to-date assessment of the
CV safety profile of linagliptin versus comparator treatments




The first cohort analyzed included all available, completed
phase 3 studies and 1 phase 2b study in the Boehringer
Ingelheim (BI) project database for linagliptin (for study de-
tails, see Table 1) in which an independent adjudication of
CV events (MACE-plus, defined as a composite end point
consisting of the following adjudicated events: CV death,
non-fatal MI, non-fatal stroke, and hospitalization for un-
stable angina) was conducted (the 8 trials with prospective
independent adjudication of hospitalization for CHF are
identified in Table 1). All studies were conducted in accord-
ance with Good Clinical Practice guidelines and the princi-
ples of the Declaration of Helsinki. This pooled patient-level
analysis was pre-specified and included only double-blind,
randomized, controlled trials, lasting ≥12 weeks, evaluating
linagliptin versus comparator (placebo or active treatment),
with database lock-up to August 6, 2012. Data from all pa-
tients treated with a daily oral linagliptin dose of 5 mg or
more were pooled into a total comparator cohort with a
common linagliptin treatment group, and all randomized
control treatments were combined into 1 common control
treatment group (regardless of whether patients were treated
with placebo or an active comparator, as per methodology
suggested by the FDA [11]). As a sensitivity analysis, the im-
pact on the primary end point 4P-MACE and on
hospitalization for CHF in the placebo cohort alone (ie, only
trials or parts of trials in which linagliptin was compared
with placebo) was also evaluated. In an additional analysis,
the occurrence of symptoms or adverse events (AEs) sug-
gestive of heart failure was evaluated, based on newly up-
dated results from 24 placebo-controlled trials (phases 1–3;
3 of which were <12 weeks in duration), involving 8778 pa-
tients (5488 linagliptin and 3290 placebo) (for details of the
additional trials included, see Table 1). Investigator-reported
AEs that may be indicative of possible heart failure were
defined using the list of terms defined in the Medical
Dictionary for Regulatory Activities (MedDRA 16.0; narrow
standardized MedDRA queries [SMQ] cardiac failure). AE-
reported terms coded to these specific MedDRA preferred
terms were used to identify possible heart failure events.
Analysis population
Common inclusion criteria across the included trials were
a diagnosis of T2DM, age ≥18 years, glycated hemoglobin
(HbA1c) 7–10% entrance criterion in most studies, and
body mass index (BMI) 20–45 kg/m2. In all studies, if de-
terioration in glycemic control occurred, rescue therapy
could be initiated. In general, rescue therapy was initiated
if glucose levels exceeded 240, 200, or 180 mg/dL (after an
overnight fast) on 2 separate days during the first 12, 12–
Table 1 Overview of linagliptin clinical trials included in the CV safety analysis of adjudicated events
Study
number
Treatment Patients Background Follow-up (weeks) Reference/NCT number
1218.15 Linagliptin 5 mg Placebo; 259 130 Pioglitazone 24 Gomis et al. [39]. NCT00641043
1218.16 Linagliptin 5 mg Placebo; 336 167 None 24 Del Prato et al. [40]. NCT00621140
1218.17 Linagliptin 5 mg Placebo; 523 177 Metformin 24 Taskinen et al. [41]. NCT00601250
1218.18 Linagliptin 5 mg Placebo; 792 263 Metformin + sulfonylurea 24 Owens et al. [42]. NCT00602472
1218.20 Linagliptin 5 mg Glimepiride 1–4 mg; 776 775 Metformin 104 NCT00622284
1218.23 Linagliptin 5 mg Linagliptin 10 mg
Voglibose 0.6 mg Placebo;
159 160 162 80 None 26 NCT00654381
1218.35 Linagliptin 5 mg Placebo; 157 81 Sulfonylurea 18 NCT00819091
1218.36* Linagliptin 5 mg Placebo; 628 627 Basal insulin ≥52 NCT00954447
1218.43 Linagliptin 5 mg Placebo; 67 63 None 52 NCT00800683
1218.46 Linagliptin 5 mg Placebo; 428 363 Metformin 24 NCT00798161
1218.50 Linagliptin 5 mg Placebo; 151 76 None 52 NCT00740051
1218.52† Linagliptin 5 mg Placebo; 396 170 Metformin 54 NCT00915772
1218.61* Linagliptin 5 mg Placebo; 183 89 Metformin + pioglitazone 24 NCT00996658
1218.62* Linagliptin 5 mg Placebo; 447 44 Metformin 12 NCT01012037
1218.63* Linagliptin 5 mg Placebo; 162 79 None 24 NCT01084005
1218.64* Linagliptin 5 mg Placebo; 113 122 None 52 NCT01087502
1218.65* Linagliptin 5 mg Placebo; 205 100 Metformin 24 NCT01215097
1218.66* Linagliptin 5 mg Placebo; 200 99 None 24 NCT01214239
1218.75* Linagliptin 5 mg Placebo; 101 115 None 24 NCT01194830
*Trials with prospective independent adjudication of hospitalization for CHF.
†Trial 1218.52 is an extension of study 1218.46 and was analyzed in conjunction with 1218.46, and therefore is not displayed as an individual study in other
displays. CV, cardiovascular; CHF, congestive heart failure.
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ation of rescue therapy were included in the analysis.
Laboratory, BP, heart rate, and weight assessment
Changes from baseline in blood pressure (BP), heart rate,
weight, and lipid parameters (including total cholesterol,
low-density lipoprotein [LDL] cholesterol, high-density
lipoprotein [HDL] cholesterol, and triglycerides) to the
last available on-treatment measurement were assessed.
CV event data collection and adjudication
Data on AEs were collected by the study investigators
using electronic case report forms. During the pivotal
phase 3 trials for linagliptin, a prospectively defined adju-
dication process was implemented to assess cardiac and
neurological vascular events, including deaths, through 2
independent, blinded, external CECs, respectively, for car-
diac events and neurological events. Adjudication for the
event ‘hospitalization for CHF’ was introduced while the
phase 3 program was in progress and, therefore, imple-
mented for a limited number of studies (8 studies, involv-
ing 3314 patients [n = 2039 linagliptin and n = 1275 total
comparators]; Table 2).
After identification of a trigger AE, a data package for the
CEC was prepared. This data package contained patientprofile information (based on the demographic and clinical
safety data in the clinical trial database); all available electro-
cardiograms and reports on angiography scans, ultrasound,
or duplex scans or echocardiography, as appropriate; all
available laboratory data; and other relevant medical docu-
ments. Based on these data packages, either the cardiac or
neurology CEC performed the adjudication of the trigger
event, blinded to treatment allocation, and documented the
adjudication result. Upon completion of a trial, these adjudi-
cated events were collected and included in the clinical trial
database.
In the additional analysis, occurrence of events suggestive
of CHF (narrow MedDRA 15.1 SMQ cardiac failure) was
assessed from the investigator-reported AEs. It should be
noted that the number of events suggestive of CHF reported
from the investigators does not take into account the adjudi-
cation status of these cases and is not limited to events lead-
ing to hospitalization.
End points
The primary end point was time to the first occurrence
of any components of the 4P-MACE composite. Second-
ary end points were composites of: (i) 3P-MACE; (ii) all
adjudicated CV events, which included CV death, non-
fatal MI, non-fatal stroke, unstable angina, stable angina,
Table 2 FDA custom MACE end point
The following MedDRA preferred terms (version 15.0) are included
in the FDA custom MACE end point:
Myocardial infarction terms Stroke terms
Myocardial Infarction terms Basilar artery thrombosis
Acute myocardial infarction Brain stem infarction
Coronary artery thrombosis Brain stem stroke
Myocardial infarction Brain stem thrombosis
Papillary muscle infarction Carotid arterial embolus
Postprocedural myocardial infarction Carotid artery thrombosis


















FDA, Food and Drug Administration; MACE, major adverse cardiovascular
event.
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custom major adverse CV events (MACE), derived from
34 MedDRA preferred terms for stroke and MI (these
terms are listed in Table 2). Tertiary end points were the
individual adjudicated end points (as listed above) plus
coronary revascularization procedures, hospitalization
for CHF, stent thrombosis, and all-cause mortality.
Statistical analysis
The analyses based on individual patient-level data in
the treated set were defined as all patients who were
randomized and received at least 1 dose of study medi-
cation. Changes in CV risk factors from baseline to last
treatment were expressed descriptively. Overall inci-
dences and incidence rates (per 1000 patient-years) were
calculated for all end points in each of the pooled treat-
ment groups within the treated set. The CV risk
estimate after treatment with linagliptin in comparison
with control treatment (and for 4P-MACE and CHF forplacebo-controlled studies only) is expressed as HR for
time to first event, using Cox proportional hazards
model, with adjustments for treatment and study groups.
Sensitivity analyses were performed to assess the impact
of rescue medication on the analyses of the primary end
point. Pre-specified subgroup analyses were performed
to evaluate the incidence and incidence rates for the
subgroup variables: age (≤50, 51 to <65, 65 to <75, and
≥75 years), gender, race, use of rescue therapy, occur-
rence of hypoglycemia, Framingham 10-year coronary
heart disease (CHD) risk score (≤15% or >15%), renal
function (estimated glomerular filtration rate [eGFR] ac-
cording to Modification of Diet in Renal Disease
[MDRD] formula), and microalbuminuria (albumin/cre-
atinine ratio [ACR]).
The number of patients with symptoms suggestive of
CHF, based on the MedDRA narrow SMQ Cardiac fail-
ure, was reported descriptively.
Results
Patient characteristics and drug exposure
Pooled data on adjudicated events were evaluated from
19 studies (17 placebo-controlled, 1 with placebo/active
control, 1 with active control only), which included
9459 patients treated with at least 1 dose of study drug.
In total, 5847 patients were treated with linagliptin; the
majority of subjects received the 5-mg dose (n = 5687)
(in study 1218.23, 160 patients received linagliptin
10 mg). There were 3612 subjects in the comparator
group: 937 received active treatment (glimepiride 1–
4 mg once daily [n = 775] or voglibose 0.2 mg 3 times
daily [n = 162]) and 2675 received placebo. Depending
on the design of the individual trial, some patients re-
ceived their trial medication in addition to existing
background glucose-lowering therapy. For the add-
itional analysis of investigator-reported CHF, data from
24 placebo-controlled studies were evaluated (patients
received linagliptin 5 mg or placebo as monotherapy, or
in addition to background therapies). This evaluation
included data from 8778 patients (5488 linagliptin- and
3290 placebo-treated patients). An overview of the in-
cluded trials is provided in Tables 1 and 3.
The overall median drug exposure in the linagliptin
group, for the main pooled analysis, was 175 days
(range: 1–776 days). Corresponding exposure in the pla-
cebo group was 174 days (range: 1–707 days), in the ac-
tive comparator group, 729 days (range: 3–804 days),
and in the combined comparator group, 183 days
(range: 1–804 days). The percentages of patients who
received trial medication for at least 52 weeks were
31.6% for placebo, 31.0% for linagliptin, 69.7% for active
control, and 42.3% for combined comparators. Cumula-
tive exposure (patient-years) was 4133.7 for linagliptin
and 3106.6 for total comparators.
Table 3 Overview of additional clinical trials included in evaluation of congestive heart failure (CHF)
Study
number
Treatment Patients Background Follow-up
(weeks)
Reference/NCT number
1218.2 Linagliptin 1, 2.5, 5, 10 mg Placebo; 35 9 None <2 Heise et al. [43]. NCT02183350
1218.3 Linagliptin, 2.5, 5, 10 mg Placebo; 61 16 None 4 Forst et al. [44]. NCT 02183415
1218.5 Linagliptin 0.5, 2.5, 5 mg Placebo; 170 67 None 30 Singh-Franco et al. [45].
NCT00328172
1218.6 Linagliptin 1, 5, 10 mg Placebo; 197 71 Metformin (most received
≥1500 mg/d)
12 Forst et al. [46]. NCT00309608
1218.37 Linagliptin 5 mg Placebo; 40 40 None 4 Rauch et al. [47]. NCT00716092
1264.3 Linagliptin 5 mg Pioglitazone
15, 30, 45 mg Linagliptin + pioglitazone;
105 284
274
None Up to 54 NCT01183013
(Study 1218.20 in table was not included in the additional analysis, as this trial was not placebo-controlled).
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treatment groups for the main pooled analysis (Table 4).
More than half of the patients were white (58.2%, lina-
gliptin group; 60.6%, total comparator group) and male
(54.4% and 56.5%, respectively). The majority of patients
were older than 50 years of age (78.0% and 78.4%, re-
spectively). Mean (SD) BMI was 29.04 (5.19) mg/kg2 in
the linagliptin group and 29.53 (5.19) mg/kg2 in the total
comparator group. More than half of the cohort (56.8%)
had a diagnosis of T2DM for >5 years, and the majority
of patients (83.1%) had previously received at least 1
glucose-lowering drug. For the 19 trials used in the main
analysis, the distribution of CV risk factors at baseline
was generally similar between the treatment groups,
with Framingham risk >15% recorded in 25% and 29% of
patients in the linagliptin and total comparator groups,
respectively. Corresponding frequencies of microalbumi-
nuria (urinary albumin:creatinine ratio [UACR], >30 to
≤300 mg/g) at baseline were 24.3% and 22.7%,
respectively.
The baseline characteristics of the dataset used for the
additional evaluation of CHF showed similar findings
(Table 5).
Active treatment produced a greater reduction in
HbA1c compared with placebo. For CV risk factors eval-
uated (total cholesterol, LDL cholesterol, HDL choles-
terol, triglycerides, systolic and diastolic BP, heart rate,
and body weight), there were no meaningful differences
between linagliptin and placebo or total comparators
(Table 6).
Adjudicated CV events
Overall, 420 patients with AEs were identified from the
pre-specified list of trigger events. A total of 60 (1.0%)
primary components of 4P-MACE events were reported
in the linagliptin group and 62 (1.7%) in the comparator
group. The incidence rate of 4P-MACE was 13.4 events
per 1000 patient-years for linagliptin-treated patients
compared with 18.9 in the active comparator group
(Table 7, Figure 1) with a Cox regression HR (Table 8)indicating no significant difference between the 2 treat-
ment groups; HR, 0.78 (95% CI, 0.55–1.12) (Figure 2).
In the placebo cohort of the overall group (ie, 18 of
the 19 trials), 4P-MACE incidence rates (Figure 3) were
14.9 per 1000 patient-years for linagliptin (43 events)
and 16.4 for total comparators (29 events), yielding an
overall HR of 1.09 (95% CI, 0.68–1.75).
In the placebo cohort (n = 7746 patients) there was no
signal for an increased risk of either all-cause or CV
mortality with linagliptin therapy. All-cause mortality for
linagliptin (2538 patient years exposure) versus placebo
(1608 patient years exposure) was reported for 13 versus
11 patients, respectively; HR 0.81 (95% CI, 0.36–1.81).
For CV mortality with linagliptin (2538 patient years ex-
posure) versus placebo (1608 patient years exposure), 8
versus 6 deaths, respectively, were reported; HR 0.88
(0.30–2.55).
Subgroup analysis of the overall cohort showed that
the risk estimate for the primary end point associated
with linagliptin versus total comparators was not in-
creased by the following factors: age, gender, race, use of
rescue therapy, occurrence of hypoglycemia, Framing-
ham 10-year CHD risk score (≤15% or >15%), renal
function, microalbuminuria, or use of background medi-
cation (insulin and/or metformin) (Table 9).
In line with the results for the primary end point, the
incidence rates and the HRs for the secondary end
points were similar for linagliptin and total comparators
(Tables 7 and 8). The overall risk estimates were also
similar for tertiary end points for linagliptin and total
comparators (Table 7, Figure 4), with a significantly re-
duced HR for stroke and TIA favoring linagliptin com-
pared with total comparators. For hospitalization for
CHF, a small number of patients reported events (n =
21), and the overall risk estimate was similar for linaglip-
tin (12 events; 2039 patients) and the total comparator
group (9 events, 1275 patients), with a HR of 1.04 (95%
CI, 0.43–2.47). This was also the case in a sensitivity
analysis of the smaller treatment cohort, excluding data
beyond 12 weeks from 1 trial (1218.64) in which 107
Table 4 Baseline demographics and clinical characteristics, including CV risk factors, of the main study cohort in the









Gender, % of patients Male/female 54.4/45.6 62.5/37.5 54.3/45.7 56.5/43.5
Age, years 59 ± 11 60 ± 10 58 ± 11 59 ± 10
BMI, kg/m2 29.0 ± 5.2 29.5 ± 4.8 29.5 ± 5.3 29.5 ± 5.2
Race, % of patients
White 58.2 70.3 57.2 60.6
Black 3.7 1.9 6.8 5.5
Asian 38.1 27.7 36.0 33.8
HbA1c, mmol/mol 65 ± 10 61 ± 9 67 ± 10 65 ± 10
HbA1c, % 8.1 ± 0.9 7.8 ± 0.9 8.3 ± 0.9 8.1 ± 0.9
FPG, mmol/L 9.2 ± 2.5 9.2 ± 2.2 9.3 ± 2.7 9.3 ± 2.6
Diabetes duration, % of patients
≤1 year 13.4 8.4 14.5 13.0
1–5 years 31.7 38.8 27.3 30.3
>5 years 54.9 52.7 58.2 56.8
Previous oral glucose-lowering agents, % of patients
None 16.4 9.6 19.4 16.8
1 43.2 64.1 39.0 45.5
2 39.3 26.1 40.0 36.0
≥3 1.1 0.1 2.1 1.6
Antidiabetic drugs at enrolment, % of patients
Metformin only 31.8 60.1 20.7 31.0
Metformin + other antidiabetic agents 38.1 25.2 38.2 34.9
Sulfonylurea only 6.5 2.0 8.0 6.5
Sulfonylurea + other antidiabetic agents 0.7 1.0 0.6 0.7
Insulin only 3.8 0.0 9.3 6.9
Insulin + other antidiabetic agents <0.1 0.0 0.0 0.0
CV risk factors, % of patients
Metabolic syndrome† 46.5 67.7 46.6 52.1
Coronary artery disease 11.8 12.3 14.1 13.6
Cerebrovascular disease 3.6 4.2 4.9 4.7
Peripheral artery disease 3.1 3.3 4.2 4.0
Hypertension 63.9 73.0 65.7 67.6
Ex-/current smoker 23.0/14.4 29.7/15.8 22.4/13.4 24.3/14.0
Microalbuminuria, % (UACR >30 to ≤300 mg/g) 24.3 21.6 23.0 22.7
Renal function based on eGFR (MDRD formula),% of patients
Normal (≥90) 43.5 43.3 41.1 41.7
Mildly impaired (60 to <90) 45.5 49.8 43.5 45.1
Moderately impaired (30 to <60) 8.9 6.8 10.8 9.7
Severely impaired (<30) 1.9 0.0 4.1 3.0
CV medication, % of patients
Acetyl-salicylic acid 31.8 32.3 34.5 33.9
Antihypertensive 60.9 69.6 62.0 64.0
Lipid-lowering therapy 41.7 49.0 43.6 45.0
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Table 4 Baseline demographics and clinical characteristics, including CV risk factors, of the main study cohort in the
linagliptin safety analysis (of adjudicated events) (Continued)
Any of the above 72.7 81.6 73.9 75.9
Framingham 10-year CV risk score
Score, % 9.7 ± 8.2 11.7 ± 8.6 9.6 ± 8.4 10.2 ± 8.5
Score >15%, % of patients 24.5 38.1 25.8 29.0
BMI, body mass index; CV, cardiovascular; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; MDRD, Modification
of Diet in Renal Disease; UACR, urinary albumin:creatinine ratio.
*Glimepiride (n = 775), voglibose (n = 162).
†International Diabetes Federation definition.
Values are mean ± SD, unless otherwise stated.
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glimepiride. In this sensitivity analysis, the total number
of adjudicated CHF events was 9 in the linagliptin group
and 5 in the placebo group, yielding a non-significant
HR of 1.29 (95% CI, 0.43–3.87).
In addition to the evaluation of hospitalization for
heart failure in the 8 studies in which adjudication took
place, further analysis of investigator-reported and non-
adjudicated events from 24 placebo-controlled studies of
linagliptin 5 mg versus placebo showed that events sug-
gestive of heart failure were reported in 0.5% (n = 26) of
linagliptin- and 0.2% (n = 8) of placebo-treated patientsTable 5 Baseline demographics and clinical characteristics, in
investigator-reported events)
Linag
Gender, % of patients Male/female 53.5/4
Age, years 58.2 ±
BMI, kg/m2 29.3 ±




HbA1c, mmol/mol 66.1 ±
HbA1c, % 8.2 ± 0
FPG, mg/dL 166.2










BMI, body mass index; CHF, congestive heart failure; CV, cardiovascular; FPG, fasting
Renal Disease.
Values are mean ± SD, unless otherwise stated.(Table 10). Among these events, those considered to be
serious were reported in 0.3% (n = 16) of linagliptin- and
0.2% (n = 6) of placebo-treated patients.
Discussion
This comprehensive pooled analysis evaluated patient-
level data from 9459 subjects with T2DM who partici-
pated in 19 clinical trials. It represents a collective 4421.3
patient-years of exposure to linagliptin—approximately
twice as many years of exposure as previous analyses. In
line with the conclusion of the previous analysis, this new
analysis also suggests that linagliptin does not increase CVcluding CV risk factors for the CHF analysis (of
liptin (n = 5488) Placebo (n = 3290)
6.5 54.9/45.1
10.6 58.1 ± 10.6




9.8 66.1 ± 9.8
.9 8.2 ± 0.9









plasma glucose; HbA1c, glycated hemoglobin; MDRD, Modification of Diet in
Table 6 Change in CV risk factors from baseline to last treatment (treated set)
Mean (SEM) Linagliptin (n = 5758) Active comparators (n = 918) Placebo (n = 2618) Total comparators (n = 3536)
Total cholesterol, mg/dL
Baseline 187 (0.6) 186 (1.3) 187 (0.9) 187 (0.8)
Change from baseline 1 (0.5) 2 (1.1) 2 (0.7) 2 (0.6)
LDL, mg/dL
Baseline 107 (0.5) 104 (1.1) 107 (0.7) 106 (0.6)
Change from baseline 1 (0.4) 4 (0.9) 1 (0.6) 1 (0.5)
HDL, mg/dL
Baseline 47 (0.2) 48 (0.4) 47 (0.3) 47 (0.2)
Change from baseline 1 (0.1) −1 (0.2) 1 (0.2) 1 (0.1)
Triglyceride, mg/dL
Baseline 173 (1.8) 180 (4.1) 174 (2.9) 176 (2.4)
Change from baseline −7 (1.5) −8 (4.2) −3 (2.6) −5 (2.2)
HbA1c, %
Baseline 8.1 (0.01) 7.8 (0.03) 8.3 (0.02) 8.1 (0.02)
Change from baseline −0.7 (0.01) −0.5 (0.03) −0.3 (0.02)* −0.3 (0.02)
Weight
Baseline 79.5 (0.25) 83.8 (0.58) 81.1 (0.39) 81.9 (0.32)
Change from baseline −0.1 (0.05) 1.3 (0.15) 0.1 (0.07) 0.4 (0.06)
Systolic BP (mmHg)
Baseline 131 (0.2) 134 (0.5) 132 (0.3) 132 (0.3)
Change from baseline −1 (0.2) −1 (0.5) −1 (0.3) −1 (0.3)
Diastolic BP (mmHg)
Baseline 78 (0.1) 80 (0.3) 78 (0.2) 79 (0.2)
Change from baseline −1 (0.1) −1 (0.3) −1 (0.2) −1 (0.2)
Heart rate, bpm
Baseline 74 (0.1) 73 (0.4) 74 (0.2) 74 (0.2)
Change from baseline 1 (0.1) −1 (0.3) 1 (0.3) 1 (0.2)
BP, blood pressure; bpm, beats per minute; CV, cardiovascular; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*Analysis includes data obtained after initiation of glycemic rescue.
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ies or versus placebo, in patients with T2DM [18]. Fur-
thermore, the findings of this analysis also indicate that
the CV risk profile was not influenced by a number of im-
portant factors associated with CV complications (age,
gender, race, use of rescue medication, occurrence of
hypoglycemia, Framingham CHD risk, renal disease, and
microalbuminuria). The findings of the present analysis
add to the existing evidence base for DPP-4 inhibitors,
which shows the class to be generally well tolerated, but
with less definitive evidence regarding CV safety [19].
To enable a relevant assessment of CV risk, studies
evaluating the CV safety of glucose-lowering therapies
should include patients at increased risk of CV events,
such as those with relatively advanced disease, elderly
patients, and those with some degree of renal impair-
ment [11]. In the present analysis, baseline data on the
Framingham risk status of participants indicated thatabout 30% of patients had a 10-year risk score of >15%,
that approximately half of all patients had been diag-
nosed with T2DM for >5 years, and that around 13% of
patients were older than 70 years of age. In addition,
some degree of renal impairment (eGFR based on
MDRD staging of <90 mL/min) was present in just over
half of patients analyzed (56.3% in the linagliptin and
57.9% in total comparator groups, respectively), with
nearly a quarter (24.3% and 22.7%, respectively) having
microalbuminuria. Thus, a sizeable proportion of the an-
alyzed population may be deemed to exhibit moderately
increased CV risk. Indeed, the observed incidence of
rates of 4P-MACE (13.4 events and 18.9 events per 1000
patient-years for linagliptin- and active comparator-
treated groups, respectively) is slightly higher than
would be predicted from the Framingham risk scores.
This observation, combined with the large number of
patients exposed to linagliptin and the higher number of
Table 7 Incidence and incidence rates of primary, secondary, and tertiary end points










CV death, stroke, MI, or UAP with hospitalization 60 (1.0) 13.4 62 (1.7) 18.9
Secondary end points
CV death, stroke, or MI 42 (0.7) 9.3 46 (1.3) 14.0
All major CV events 96 (1.6) 21.5 95 (2.6) 29.1
FDA-custom MACE 39 (0.7) 8.7 45 (1.3) 13.7
Tertiary end points
CV death 11 (0.2) 2.4 8 (0.2) 2.4
Non-fatal MI 23 (0.4) 5.1 20 (0.6) 6.1
Non-fatal stroke 9 (0.2) 2.0 19 (0.5) 5.8
TIA 1 (0.02) 0.2 8 (0.2) 2.4
UAP with hospitalization 22 (0.4) 4.9 16 (0.4) 4.8
Hospitalization for CHF* 12 (0.6) 8.8 9 (0.7) 8.4
Total mortality 18 (0.3) 4.0 16 (0.4) 4.8
CHF, congestive heart failure; CV, cardiovascular; FDA, Food and Drug Administration; MACE, major adverse CV events; MI, myocardial infarction; TIA, transient
ischemic attack; UAP, unstable angina pectoris.
*Includes data only from trials with prospective independent adjudication of hospitalization for CHF (n = 3314).
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therefore, supports the validity of the findings.
As noted above, the incidence of CV events reported
in this analysis, per 1000 patient-years of exposure, was
13.4 for linagliptin and 18.9 for total comparators. Other,
similar, analyses of phase 3 studies have reported inci-
dence rates for custom MACE ranging from 5.8 to 14.6
for sitagliptin, saxagliptin, or vildagliptin, and 9.0 to 14.1
for pooled comparators [20-22]. The most recent assess-
ment of the CV safety of sitagliptin, based on pooled
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Figure 1 Time to first event (occurrence of any component of the 4P-MAC
patients receiving linagliptin versus total comparators. CV, cardiovascular; Mrate ratio, per 100 patient-years, of 0.83 (95% CI, 0.53–
1.30) for the comparison of sitagliptin versus pooled
comparators, and 1.01 (95% CI, 0.55–1.86) for sitagliptin
versus placebo [23]. These findings are in line with the
results of the present analysis. Although the previous
analyses of the CV safety of DPP-4 inhibitors differ in
their methods, the findings nonetheless support the hy-
pothesis that, in general, DPP-4 inhibitor therapy is not
associated with increased CV risk. This was also sup-
ported by the neutral outcomes on 3P-MACE of the
prospective studies SAVOR-TIMI 53 and EXAMINE,rators
e (weeks)
0 60 70 80 90 100 110 120
71 1292 1119 804 639 599 3 0
27 1115 967 750 631 608 3 0
E composite of CV death, MI, stroke, or UAP with hospitalization) for
I, myocardial infarction; UAP, unstable angina pectoris.
Table 8 Risk for primary, secondary, and tertiary
individual CV end points with linagliptin versus total
comparators based on Cox proportional hazards model
Cox HR (95% CI)
Primary end point
CV death, MI, stroke, or 0.78 (0.55–1.12)
UAP with hospitalization
Secondary end points
CV death, stroke, or MI 0.74 (0.49–1.13)
All major CV events 0.82 (0.61–1.09)
FDA-custom MACE 0.70 (0.45–1.08)
Tertiary end points
CV death 1.04 (0.42–2.60)
Non-fatal MI 0.86 (0.47–1.56)
Non-fatal stroke 0.34 (0.15–0.75)
TIA 0.09 (0.01–0.75)
UAP with hospitalization 1.08 (0.56–2.06)
Hospitalization for CHF* 1.04 (0.43–2.47)
Total mortality 0.89 (0.45–1.75)
CHF, congestive heart failure; CI, confidence interval; CV, cardiovascular; FDA,
Food and Drug Administration; HR, hazard ratio; MACE, major adverse CV
events; MI, myocardial infarction; TIA, transient ischemic attack; UAP, unstable
angina pectoris.
*Includes data only from 8 trials with prospective independent adjudication of
hospitalization for CHF (n = 3314).
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[12,13].
EXAMINE was designed to investigate the CV risk of
alogliptin compared with placebo in patients with T2DM
and recent acute coronary syndrome [13]. Similar rates
of major CV AEs in addition to CV or all-cause mortal-
ity were reported for alogliptin- and placebo-treated pa-
tients. The SAVOR TIMI 53 trial evaluated the effects of0.1
RR (CMH with
continuity correction
according to treatment arm)
RR (CMH with














Figure 2 Risk estimates for primary composite CV end point with linaglipti
confidence interval; CMH, Cochran-Mantel-Haenszel; CV, cardiovascular; HR,saxagliptin on CV outcomes in patients with T2DM at
high CV risk. No difference in the primary composite
end point of CV death, MI, or ischemic stroke was
found in saxagliptin- or placebo-treated patients [12]. It
should be noted that both of these trials were relatively
short in duration (median follow-up, respectively, 2.2
and 1.5 years) and included patients predominantly, or
exclusively, with manifest CV complications, 2 important
considerations when assessing the potential CV risk
modulation of any compound [24,25].
The unexpected finding of an increased risk of CHF in
these trials merits further careful evaluation [12,14,15].
A recent study of echocardiograms from 254 patients
with T2DM and existing CHF (New York Heart Associ-
ation [NYHA] class I to III), who received vildagliptin or
placebo for 52 weeks, found that vildagliptin therapy did
not change the cardiac ejection fraction (the primary
end point of the study), and was not associated with
worsening of CHF (confirmed by a blinded adjudication
committee); worsening CHF occurred in 22 patients in
the placebo group compared with 23 in the vildagliptin
group [26]. However, patients taking vildagliptin, com-
pared with those taking placebo, showed unexpected
increases in left ventricular end-diastolic volume
(P = .007), end-systolic volume (P = .06), and stroke
volume (P = .002). The possible mechanisms underlying
these observations are not fully understood. Two recent
meta-analyses of available data from randomized clinical
trials of DPP-4 inhibitors have indicated that these drugs
could be associated with an increased risk of acute heart
failure [27,28]. However, both meta-analyses included
data from the SAVOR-TIMI 53 trial, the results of which
strongly influence the overall findings. Furthermore, a
new analysis of data from EXAMINE, presented at the
Scientific Sessions of the American College of1 10
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Figure 3 Time to first event (occurrence of any component of the 4P-MACE composite) for patients receiving linagliptin versus placebo.
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not increase the risk of new-onset heart failure or the
risk of readmission in patients with T2DM and a history
of heart failure [29]. In the linagliptin clinical trial pro-
gram, adjudication of hospitalization for CHF was imple-
mented during phase 3b. Given the small number of
reported cases of CHF (for the overall comparator ana-
lysis, n = 12 and n = 9; and for the comparison with pla-
cebo only, n = 9 and n = 5), the reported HR of 1.04
(95% CI, 0.43–2.47) in the overall comparator analysis,
or 1.29 (95% CI, 0.43–3.87) in the placebo-only analysis
must be interpreted with some caution. Similarly, in the
additional analysis of investigator-reported AEs in 24
placebo-controlled studies, the occurrence of events sug-
gestive of heart failure was low (0.5% [n = 26 of 5488]
and 0.2% [n = 8 of 3290] for linagliptin- and placebo-
treated patients, respectively), and was within the ex-
pected background incidence for this population. There-
fore, this database is currently too small to allow firm
conclusions to be made regarding the impact of linaglip-
tin on the risk of heart failure. So far, there has been no
explanation for the increase in risk of CHF observed in
the trials mentioned above, and data are currently lim-
ited. However, it has been noted that trials with reported
CV outcomes tend to include patients who are older,
have a longer duration of T2DM, more CV risk factors,
lower renal function, more comorbidities, and often
treated with a greater number of antidiabetic drugs, in-
cluding insulin, when compared with other studies of
patients with T2DM [19]. These factors might be rele-
vant in the identification of subpopulations who could
be at increased risk of CHF or other CV outcomes with
DPP-4 inhibitor therapy. Reassuringly, a review of safety
data for DPP-4 inhibitors has demonstrated the safety
and tolerability of these agents in fragile populations
such as elderly patients and individuals with renalimpairment [30]. Similarly, a recent pooled analysis of 6
clinical trials demonstrated the safety and tolerability of
linagliptin in a vulnerable subpopulation of patients at
high risk of renal or CV disease [31]. A recent system-
atic review and network meta-analysis of 10 clinical tri-
als of DPP-4 inhibitors in patients requiring third-line
therapy for T2DM showed no difference between these
agents and placebo in the incidence of adverse events,
including CVD [32]. This analysis thus provides further
evidence of the safety and tolerability of DPP-4 inhibi-
tors in patients with T2DM that is difficult to control.
The ongoing Trial Evaluating Cardiovascular Out-
comes with Sitagliptin (TECOS), designed to test the hy-
pothesis that sitagliptin added to usual diabetes care
does not increase CV risk in patients with existing CVD
(estimated mean trial duration, approximately 4 years)
[33], will also provide an evaluation of DPP-4 inhibitor
therapy over a longer period than SAVOR-TIMI 53 or
EXAMINE, and should provide additional information
on the CHF issue.
An interesting finding of the present pooled analysis is
the significant reduction in cerebrovascular end points
observed in linagliptin-treated patients, compared with
the other groups, albeit limited by small number of ob-
servations. This finding would need to be further evalu-
ated, in particular because similar results were not
observed in the recent SAVOR-TIMI 53 and EXAMINE
trials [12-14]. Whether linagliptin could offer benefits
following stroke is another possible area for further re-
search in light of preclinical findings that have demon-
strated a glucose-independent neuroprotective effect of
linagliptin in the diabetic mouse brain model, possibly as
a result of neural stem cell proliferation [34]. Potential
improvements in endothelial function with DPP-4 inhib-
ition, as indicated in some studies, could have implica-
tions for cerebrovascular outcomes [35,36]. The impact
Table 9 Subgroup analyses of primary end point for linagliptin versus total comparators based on proportional Cox








(95% CI) CMH Test
Age (years)
≤50 5/1288 3/781 1.31 (0.31–5.58) 1.11 (0.47–2.63)
51 to <65 26/2817 26/1740 0.75 (0.43–1.30) 0.86 (0.52–1.41)
65 to 75 26/1418 29/902 0.78 (0.46–1.32) 0.84 (0.52–1.37)
≥75 3/324 4/189 0.63 (0.14–2.85) 0.88 (0.37–2.08)
Gender
Male 42/3183 50/2039 0.69 (0.45–1.04) 0.73 (0.49–1.08)
Female 18/2664 12/1573 1.22 (0.58–2.55) 1.27 (0.68–2.36)
Race
White 46/3405 49/2190 0.78 (0.52–1.17) 0.83 (0.56–1.23)
Black 4/215 1/200 3.92 (0.44–35.08) 1.50 (0.55–4.11)
Asian 10/2227 12/1222 0.59 (0.25–1.37) 0.76 (0.39–1.49)
Use of rescue medication
No 43/5080 46/2824 0.70 (0.46–1.07) 0.75 (0.50–1.12)
Yes 17/767 16/788 1.10 (0.56–2.19) 1.11 (0.64–1.91)
Investigator-reported hypoglycemia
No 48/5197 37/2918 0.86 (0.56–1.32) 0.97 (0.65–1.45)
Yes 12/650 25/694 0.79 (0.39–1.59) 0.78 (0.41–1.47)
Framingham 10-year CV risk score
≤15% 20/3797 24/2438 0.65 (0.36–1.18) 0.76 (0.45–1.29)
>15% 36/1433 38/1046 0.85 (0.54–1.35) 0.91 (0.60–1.39)
Baseline microalbuminuria
Normal (≤30 mg/g) 25/3610 25/2389 0.84 (0.48–1.47) 0.91 (0.56–1.50)
Elevated (>30 to ≤300 mg/g) 21/1248 21/771 0.75 (0.41–1.38) 0.83 (0.49–1.41)
High (>300 mg/g) 6/280 14/241 0.43 (0.16–1.11) 0.63 (0.31–1.26)
CI, confidence interval; CV, cardiovascular; HR, hazard ratio; CMH test, Cochran-Mantel-Haenszel test with treatment arm continuity correction.
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function is currently under investigation in 2 outcome
trials, as discussed below.
As with all pooled analyses, the present analysis has
several limitations; in particular, the relatively short and
different durations of the included studies limit the ex-
tent of interpretations that can be made. Furthermore,
despite a large cumulative patient exposure to linaglip-
tin, individual patient exposure was for a maximum of
2.2 years, so the time available for the development of
CV events, or modulation of CV risk, was limited. As
might be expected, only a relatively small proportion of
patients received triple therapy or insulin therapy at
baseline, suggesting that a relatively limited number of
patients in the study population had advanced T2DM.
However, the robustness of the findings of the present
study is supported by its pre-specified design, which in-
corporated independent prospective, blinded adjudica-
tion of CV events, and by the consistency of the results,both across the individual trials and across the different
pools of results. However, none of the individual studies
included in our analysis was powered or designed to as-
sess CV risk or events.
Two ongoing CV outcome trials of linagliptin will pro-
vide a more definitive answer on the CV safety profile of
linagliptin. One of these trials, the CARdiovascular Out-
come Study of LINAgliptin versus Glimepiride in Pa-
tients with Type 2 Diabetes (CAROLINA®) [37,38]
(NCT01243424) started in 2010 and has randomized
6041 patients with early T2DM and predominantly
medium CV risk, to treatment with either linagliptin or
glimepiride. CAROLINA® is the first head-to-head CV
outcome trial of a DPP-4 inhibitor versus active com-
parator that is sufficiently powered to demonstrate po-
tential differences in CV events between treatment
groups. CAROLINA® will allow an assessment of the im-
pact of long-term linagliptin therapy in a population at
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Figure 4 HR estimates for secondary composite CV end points with linagliptin versus total comparators based on Cox hazard model. CI,
confidence interval; CV, cardiovascular; FDA, Food and Drug Administration; HR, hazard ratio; MACE, major adverse CV events; MI,
myocardial infarction.
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comparator glimepiride.
The second CV outcome study, CARdiovascular
Safety & Clinical outcoME with LINAgliptin (CARME-
LINA®), will compare the CV and renal safety of linaglip-
tin versus placebo, when added to standard care in
approximately 8300 patients with T2DM at high CV and
renal compromise, and is the only large outcome study
dedicated to the evaluation of tangible renal outcomes
with a DPP-4 inhibitor in comparison with placebo. TheTable 10 Occurrence of adverse events suggestive of
heart failure in 24 placebo-controlled trials of linagliptin
Linagliptin Placebo
(n = 5488) (n = 3290)
Cardiac failure (narrow SMQ)*, n (%) 26 (0.5) 8 (0.2)
Acute pulmonary edema 1 (0.0) 1 (0.0)
Cardiac failure 6 (0.1) 2 (0.1)
Cardiac failure, acute 2 (0.0) 0 (0.0)
Cardiac failure, chronic 1 (0.0) 0 (0.0)
Cardiac failure, congestive 7 (0.1) 5 (0.2)
Cardiogenic shock 2 (0.0) 0 (0.0)
Cardiopulmonary failure 1 (0.0) 0 (0.0)
Left ventricular failure 6 (0.1) 0 (0.0)
Pulmonary edema 1 (0.0) 2 (0.1)
Right ventricular failure 1 (0.0) 0 (0.0)
MedDRA, Medical Dictionary for Regulatory Activities; SMQ, standardized
MedDRA queries.
Data are based on MedDRA version 16.0.
*Heart failure data are a total of the narrow SMQ listed. Individual patients
may have had >1 event.CARMELINA® trial was initiated in 2013 and results are
expected between 2017 and 2018.
Conclusion
This large patient-level pooled safety analysis of linaglip-
tin supports previous findings that linagliptin is not as-
sociated with an increase in CV risk, compared with a
pooled comparator group of placebo, glimepiride, or
voglibose, in patients with T2DM, irrespective of back-
ground therapy. In this analysis, linagliptin has been
shown to be effective in improving glycemic control in a
broad range of patients with type 2 diabetes including
elderly patients and those with renal impairment. The
data presented here could help to reassure clinicians
prescribing linagliptin to their patients that they do so
without increasing CV risk. The ongoing CAROLINA®
and CARMELINA® studies will provide definitive data
on the CV safety of linagliptin.
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